Description Module
The Description Module contains narrative descriptions of the clinical trial, including a brief summary and detailed description. These descriptions provide important information about the study's purpose, methodology, and key details in language accessible to both researchers and the general public.
Description Module path is as follows:
Study -> Protocol Section -> Description Module
Description Module
Ignite Creation Date:
2025-12-24 @ 1:38 PM
Ignite Modification Date:
2025-12-24 @ 1:38 PM
NCT ID:
NCT00760695
Brief Summary:
A pilot study designed to reveal the effects of Marinol / dronabinol, a CB 1 agonist.
Primary end point: To estimate weight gain and EDI scores in patients receiving Marinol compared to placebo
Secondary end points: Motor and inner restlessness and hormonal changes during the treatment.
Detailed Description:
The goals of this study are to reveal through a pilot trial if treatment of patients with severe chronic AN with Marinol® (dronabinol, a CB1 agonist) has significant effect on:
* Weight
* Eating Disorder Inventory (EDI) scale
* Motor and inner restlessness (estimated by accelerometry)
* Endocrine parameters (see below, paragraph 4.4) This study is a randomized, double blinded, placebo controlled cross over study. 24 patients with chronic AN meeting the inclusion criteria will be randomized either to receive Marinol® or placebo. After four weeks the two groups will undergo a wash-out period and after that will receive the opposite therapeutic regime for another four weeks.
Study:
NCT00760695
Study Brief:
Protocol Section:
NCT00760695